Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Intelligent Searching Tool Enables Biochemical Lead Identification and Patent Fortification

By BiotechDaily International staff writers
Posted on 29 Jan 2013
A new intelligent database searching system provides virtual screening to identify biologically active molecules for a broad range of applications.

Cresset Group (Welwyn Garden City, UK) completes its Cresset proV10 suite with the relaunch of its highly successful FieldScreen system as “blazeV10” for ligand based virtual screening. Based on the shape and electrostatic character of known ligands, blazeV10 rapidly searches large chemical collections for molecules with similar properties, returning diverse new leads. This makes it a powerful tool for patent fortification and compound reprofiling.

blazeV10 is used to find biologically active molecules in a broad range of situations across the pharmaceutical, agrochemical, and fine chemical industries. Performing a virtual screen with blazeV10 before a wet screening run can dramatically increase the hit rate, cutting costs and speeding up the discovery process. Applying blazeV10 to HTS results identifies molecules, which falsely failed the biological assay, rescuing them for further investigation. Using blazeV10 on compounds of known biological activity provides insights into off-target effects. Employing blazeV10 to search databases of known drugs identifies potential reprofiling opportunities. Cresset consultants use blazeV10 to advise clients on how to strengthen their patent position by identifying structurally diverse compounds that could be potential fast followers.

“The relaunch of one of our leading applications as blazeV10 completes the rebranding of the Cresset range of software for molecular design and discovery. blazeV10, sparkV10, torchV10, and forgeV10 are outstanding tools that help chemists design and discover the best new active molecules for life science research,” said Dr. Robert Scoffin, CEO of Cresset.

blazeV10 is operated through a simple web based wizard like interface or as a series of command line applications and is available as software for installation, software as a service running on cloud hardware, or through consultancy with Cresset’s project services team.

Related Links:

Cresset Group, Ltd.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.